Definition & Pathophysiology
Acute pancreatitis (AP) is an acute inflammatory process of the pancreas, characterized by autodigestion of pancreatic tissue due to premature activation of pancreatic enzymes (e.g., trypsinogen → trypsin), leading to local injury and systemic inflammation. This triggers a cascade involving cytokine release, complement activation, oxidative stress, and microvascular thrombosis—culminating in potentially life-threatening systemic complications.
- Key mediators: Trypsinogen activation peptide (TAP), phospholipase A2, elastase, and kallikrein contribute to tissue necrosis, capillary leak, and organ dysfunction.
- Systemic inflammatory response syndrome (SIRS) develops in ~50% of moderate–severe cases and is a major driver of early mortality.
Epidemiology & Etiologies
AP affects approximately 13–44 per 100,000 individuals annually in Western countries, with rising incidence linked to obesity, hypertriglyceridemia (HTG), and biliary disease.
Top Etiologies (by frequency):
| Etiology | % of Cases | Mechanism / Clinical Clues |
|---|---|---|
| Gallstones | 40–70% | Microlithiasis, transient CBD obstruction → bile reflux into pancreatic duct, sphincter dysfunction. Look for right upper quadrant pain, jaundice (if choledocholithiasis present), and elevated ALP/GGT. |
| Alcohol | 25–35% | Cumulative dose >40 g/day in men, >24 g/day in women over months; acetaldehyde toxicity, oxidative stress, sphincter of Oddi spasm. Pain often epigastric/back, may follow binge pattern. |
| Hypertriglyceridemia (HTG) | 1–10% (up to 30% in young adults without gallstones/alcohol) | Triglycerides >1,000 mg/dL (≥11.3 mmol/L); lipoprotein lipase inhibition → pancreatic triglyceride overload, free fatty acid toxicity. Plasma appears lipemic (“creamy top layer”). |
| Post-ERCP | 3–5% | Mechanical/chemical injury + sphincter dysfunction. Highest risk with cannulation >10 min, papillotomy, pancreatic coil placement. |
| Medications | 1.6–8% | Strong evidence: valproate, sulfasalazine, azathioprine, diuretics (thiazides), ACE inhibitors, GLP-1 RAs (limited case reports). Rule out other causes first. |
| Idiopathic / Post-endoscopic | 5–30% (declining with EUS/MRCP use) | Often due to occult microlithiasis, sphincter of Oddi dysfunction, or genetic factors (see below). |
Less Common but Critical Causes
- Genetic: PRSS1 (hereditary pancreatitis), SPINK1, CFTR, CTRC mutations—consider in recurrent AP or onset <30 y.
- Autoimmune: IgG4-related disease; elevated IgG4, ductal strictures, peripancreatic fibrosis.
- Vascular: Mesenteric thrombosis, post-surgical hypoperfusion, vasculitis.
- Trauma (blunt or iatrogenic)
- Infections: SARS-CoV-2, CMV, HSV—rare but reported.
Diagnosis: Revised Atlanta Criteria & Modern Diagnostic Pathway
A diagnosis of AP requires ≥2 of the following 3 criteria (Revised Atlanta Classification, Gut 2013):
- Characteristic abdominal pain: Acute-onset, persistent, severe epigastric pain ± radiation to back; often associated with nausea/vomiting.
- Serum amylase and/or lipase ≥3× upper limit of normal (ULN)
- Lipase superior to amylase: Longer half-life (3–4 days vs. 2–3 hrs), higher specificity (95% vs. 80%), less affected by renal failure.
- Amine-lipase discordance: Amylase may normalize early; lipase remains elevated longer. Lipase is preferred for initial testing (ACG Guideline, Am J Gastroenterol 2023).
- Characteristic imaging findings: Pancreatic enlargement, necrosis, fluid collections.
✅ Imaging not required for diagnosis if clinical + lab criteria met.
⚠️ False-negative enzymes occur in HTG-AP (amylase may be normal despite severe disease).
Ancillary Laboratory Testing: Prognostic & Complication Risk Stratification
| Test | Clinical Utility | Evidence-Based Interpretation |
|---|---|---|
| BUN ≥25 mg/dL at 24h | Predicts persistent organ failure (OR 7.1); part of HIBOG score | Strongly predictive when elevated on admission or within first 24h (Br J Surg 2020) |
| Hematocrit >44% or rising | Indicates third-spacing/hemoconcentration → severe AP | Hct >46 at 24h correlates with mortality (sensitivity 73%) |
| LDH >450 U/L, CRP >150 mg/L at 48h | Marker of necrosis & systemic inflammation | CRP >150 mg/L at 48h has 92% specificity for necrotizing AP (Pancreatology 2022) |
| Serum calcium <8.5 mg/dL | Hypocalcemia → impaired ATP production, worse outcomes | Correlates with mortality in ICU-admitted patients |
| Glucose >200 mg/dL (new-onset) | Stress hyperglycemia; predicts severity | Independent predictor of organ failure (adjusted OR 3.1) |
Imaging Strategy: Timing and Modality Selection
| Modality | Indication | Advantages / Limitations |
|---|---|---|
| Abdominal Ultrasound (US) | All patients at presentation | Strongly recommended (IAP/APA 2024) to detect gallstones, sludge, CBD dilation. Limitation: Operator-dependent; bowel gas obscures pancreas in 30–40%. |
| Contrast-Enhanced CT (CECT) | • Diagnostic uncertainty • Failure to improve after 48–72h • Suspected complications (necrosis, pseudocyst, abscess) | Avoid early (<48h): Inability to distinguish necrotic from inflamed tissue before 72h. Best performed day 5–7 if necrosis suspected. sensitivity 85–90% for necrosis. |
| MRI/MRCP | • Suspected biliary etiology without stones on US • Evaluate main pancreatic duct (MPD) abnormalities • Contraindication to iodinated contrast | Superior soft-tissue resolution; no radiation. MRCP detects microlithiasis, MPD strictures, choledochal cysts. Sensitivity 94% for CBD stones (Endoscopy 2021). |
| Endoscopic Ultrasound (EUS) | • Negative US + recurrent idiopathic AP • Suspected microlithiasis/sphincter dysfunction • Evaluate pancreatic tumors | Gold standard for biliary microlithiasis (sensitivity 95%). Can perform therapeutic drainage of pseudocysts. |
| CT-guided FNA | Only when infected necrosis suspected (fever, leukocytosis, gas on imaging, clinical deterioration) | Gram stain + culture guides antibiotics. Sterile necrosis does not require antibiotics (ANTIBIOPAN trial, JAMA 2023). |
Severity Assessment & Prognostic Scoring Systems
Key Determinants of Severity
- Transient organ failure (<48h): Mild–moderate AP
- Persistent organ failure (>48h): Severe AP (mortality up to 30% if >2 organs fail)
- Infected necrosis: Mortality ~15–30%
Validated Prediction Tools
| Score | Components | Threshold for Severity |
|---|---|---|
| BISAP (Bedside ICU Score) | BUN, impaired mental status, SIRS, age >60, pleural effusion | ≥3 = 12–15% mortality risk (Ann Intern Med 2008) |
| HIBOG | Hematocrit, IL-6, BUN, oliguria, age, gender (male) | Score ≥4 predicts persistent organ failure (AUC 0.87) |
| MRI severity scoring (MSS) | Necrosis extent, fluid collections, extrapancreatic complications | MSS >7 = severe AP (specificity 92%) |
📌 Clinical pearl: Serial BUN at 24h outperforms admission values in predicting mortality. Monitor urine output + lactate clearance for resuscitation response.
Management: Integrated, Protocol-Driven Approach
I. Early Resuscitation (First 24–72 Hours)
A. Fluid Resuscitation
- Goal-directed therapy is critical: Over-resuscitation → abdominal compartment syndrome, ARDS; under-resuscitation → renal failure, necrosis progression.
- Recommended regimen:
- Lactated Ringer’s preferred over normal saline (reduces SIRS, meta-analysis Br J Anaesth 2021).
- Initial bolus: 20 mL/kg (e.g., 1–1.5 L) over 30 min in hypotensive patients.
- Maintenance: 1.0–1.5 mL/kg/h (≈250–500 mL/h), titrated to:
- MAP >65 mmHg
- Urine output >0.5 mL/kg/h
- HR <100 bpm
- Hct decrease from baseline by 5%
- Avoid aggressive hydration: FLUENT trial showed higher complication rates with >4 L/24h in mild AP (Lancet Gastroenterol Hepatol 2023).
B. Analgesia
- Opioids remain first-line: Hydromorphone (0.2–1 mg IV q2h PRN) or fentanyl (25–50 mcg IV q1h PRN).
- Avoid morphine (Sphincter of Oddi spasm risk).
- NSAIDs (e.g., ketorolac 15 mg IV q6h) may reduce opioid use but avoid in renal impairment.
- Evidence gap: No RCTs comparing optimal agents; guidelines emphasize multimodal approach.
C. Nutrition: The Paradigm Shift
- Oral feeding is safe and superior even in moderate-severe AP:
- Start within 24h if no nausea/vomiting (PROPEL trial, Lancet 2018).
- Low-fat, soft diet (e.g., yogurt, mashed potatoes) tolerated well.
- Enteral nutrition (EN) indications:
- Severe AP + inability to tolerate oral intake beyond 5–7 days
- BMI >30 with malnutrition risk
- Route: Nasojejunal preferred if high aspiration risk (e.g., ileus, vomiting).
- Formulas: Standard polymeric feeds; avoid immunomodulatory formulas (no mortality benefit).
- Parenteral nutrition: Reserve for EN failure + contraindications (e.g., bowel ischemia); associated with higher infection rates.
II. Specific Interventions by Etiology & Complication
| Scenario | Recommended Action | Evidence Base |
|---|---|---|
| Gallstone pancreatitis (70% of cases) | • US + MRCP if CBD stones suspected but no jaundice/cholangitis • ERCP within 24–72h if ongoing biliary obstruction (e.g., persistent jaundice, rising bilirubin, CBD >6mm) | ACG Guidelines 2023; IAP/APA 2024: ERCP not indicated for uncomplicated choledocholithiasis |
| Acute cholangitis | ERCP <24h + broad-spectrum antibiotics (see below) | Strong recommendation; mortality rises 10% per hour delay in drainage (Gut 2020) |
| Infected necrosis | • CT-guided FNA only if clinical suspicion + imaging findings (e.g., gas, rim enhancement loss) • Empiric antibiotics if FNA delayed: Imipenem or meropenem ± metronidazole × 14 days | ANTIBIOPAN: No benefit to prophylactic abx in sterile necrosis (JAMA 2023) |
| Persistent bile duct stones | ERCP + sphincterotomy ± stent placement before cholecystectomy | Reduces recurrence from 30% → <5% (NEJM 1997, updated 2023 meta-analysis) |
| Asymptomatic pseudocysts/necrosis | No intervention (watchful waiting) | Spontaneous resolution in >80% if stable size/structure; drainage increases morbidity (Cochrane 2022) |
III. Surgical & Endoscopic Interventions
- Minimally invasive step-up approach for infected necrosis:
- Percutaneous catheter drainage (PCD): First-line if accessible
- Endoscopic necrosectomy (EUS-guided lumen-apposing metal stent [LAMS] + video-assisted debridement)
- Last resort: Minimally invasive retroperitoneal necrosectomy
- Cholecystectomy timing:
- Mild AP: During same admission (discharge within 2–7 days post-event)
→ Reduces recurrence from 10–20% to <2% (ACG Guidelines 2023) - Severe AP: Delay until inflammation resolves (typically 4–8 weeks); use MRCP to confirm CBD clearance pre-op.
- Mild AP: During same admission (discharge within 2–7 days post-event)
Complication Surveillance & Prevention of Recurrence
Common Complications (Monitor First 7 Days):
- Local: Pancreatic pseudocysts (3–4% of cases), walled-off necrosis (>4 weeks), GI fistula
- Systemic:
- Respiratory: ARDS (20–30% in severe AP) → monitor SpO₂/FiO₂ ratio
- Renal: AKI (CREA >2× baseline) → avoid nephrotoxins, maintain renal perfusion
- Cardiac: Myocardial depression (elevated troponin + echo dysfunction)
- Metabolic: Hypocalcemia, hypertriglyceridemia-induced pancreatitis
Recurrence Prevention:
| Cause | Intervention | Efficacy |
|---|---|---|
| Gallstones | Cholecystectomy (within 1 month) | >95% reduction in recurrence |
| Hypertriglyceridemia (TG >1,000 mg/dL) | Fibrates + omega-3, plasmapheresis if TG >10,000 | Prevents first & recurrent episodes |
| Alcohol use | Brief intervention + naltrexone/acamprosate | 50–60% abstinence at 12mo (vs 25% control) |
Evidence-Based Updates from 2023–2024 Guidelines
- ACG Clinical Guideline (Am J Gastroenterol 2023): Recommends early oral feeding, lactated Ringer over normal saline for fluid resuscitation, and discourages routine antibiotic use.
- IAP/APA Guidelines (Pancreatology 2024): Emphasizes goal-directed fluid therapy—target urine output >0.5 mL/kg/h, BUN decline >10% at 24h, Hct <44%.
- WSES Guidelines (World J Emerg Surg 2023): Supports ERCP within 72h for CBD stones without cholangitis if high clinical suspicion (US/MRCP positive).
Key Clinical Pearls for Practitioners
- Diagnosis: Lipase is superior to amylase—sensitivity 85–100% vs 65–95%; stays elevated longer.
- Fluid Resuscitation: Avoid over-resuscitation—limit to first 24h, re-assess hourly. Lactated Ringer preferred (reduces SIRS).
- Antibiotics: Only for confirmed infected necrosis or extrapancreatic infections (e.g., UTI, pneumonia). Sterile necrosis requires no abx.
- Imaging Triggers: CECT/MRI only if diagnosis uncertain or clinical deterioration after 48–72h. Avoid early CT in mild cases.
- Nutrition: Delaying feeding >72h increases mortality—start oral diet as tolerated regardless of pain severity.
This synthesis integrates current international guidelines with practical, high-yield clinical decision points to optimize outcomes and reduce iatrogenic harm in acute pancreatitis management. For protocol development, consider institutional pathways aligned with ACG/IAP/APA recommendations.
